FindTrial
Sign In

A Clinical Study to Assess Skin Brightening and Safety of Exolux Night Cream in Healthy Individuals

An Open-Label, Single-Arm, Interventional Clinical Study to Evaluate the Non-Comedogenicity, Safety, and Skin Brightening Efficacy of Exolux Night Cream in Healthy Adult Subjects Over 14 Days - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/109672
Enrollment
34
Registered
2026-04-28
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Exolux Night Cream: one daily topical application at night for 14 Days. Control Intervention1: EXOLUX Night Cream: This is an interventional, open-label, single-arm study with no compar
no comparator or control arm is included.

Sponsors

SKINOVATE LASER & COSMETIC SURGERY CENTRE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Healthy males and females aged 18 to 65 years No active dermatological conditions Medically stable with no clinically significant abnormalities All skin types including normal dry oily and combination Fitzpatrick skin types I to IV Willing to provide written informed consent

Exclusion criteria

Exclusion criteria: Pregnant or lactating women will be excluded from the study. Subjects with any significant dermatological or systemic disease that may interfere with study evaluations, including active dermatoses, will not be eligible. Individuals presenting with acne having a total lesion count (TLC) greater than 10 at baseline, known photosensitivity disorders, dermatographism, or immunocompromised status will be excluded. Subjects with a known history of hypersensitivity or allergy to any component of the study product will not be enrolled. Participants who have used medications that may interfere with study outcomes, including systemic or topical steroids, non-steroidal anti-inflammatory drugs (NSAIDs), or antihistamines within the past 2 weeks, and retinoids within the past 1 month, will be excluded. Additionally, individuals who have received any vaccination within 3 weeks prior to screening, participated in another clinical study within the past 30 days, or have a history of substance abuse will not be considered eligible for participation.

Design outcomes

Primary

MeasureTime frame
To evaluate the non-comedogenic potential of Exolux Night Cream based on changes in total lesion count (TLC)Timepoint: 14 days 34 subjects—

Secondary

MeasureTime frame
To assess skin irritation potential using Draize scoring. To evaluate skin brightness and overall appearance. To assess safety and tolerabilityTimepoint: 14 days 34 subjects—

Countries

India

Contacts

Public ContactDr Avinash Bajirao Jadhav

Punawale Multispecialty Hospital

dr.avinashjadhav2@gmail.com7378306651

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026